drugset / Trial / NCT04560738

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

NCT04560738

Phase 1 Completed 8 enrolled Celgene Corporation
NaSingle-groupOpen-labelOther

Summary

This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of \[14C\]-CC-92480 and to evaluate the safety and tolerability of \[14C\]-CC-92480 following a single oral dose of \[14C\]-CC-92480.

Timeline

Start
2020-10-15
Primary completion
2021-05-13
Completion
2021-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Mezigdomide Small molecule Oral

Indications

No indication recorded.